Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 245

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 245
---

of 19%. As of February 28, 2025, the ADDF warrants had expired.

The ADDF
Note was subsequently converted in accordance with its terms, in May 2023 into 101,806 shares of common stock.

Founders Equity

DiamiR was capitalized
by its two founders with a cash contribution by one of its founders of $250,000 for 2,200,000 shares of common stock and a non-cash contribution
by the other founder for 2,000,000 shares of common stock. The non-cash contribution consisted of all of the founders’ rights, title,
and interest in any intellectual property, proprietary property or other property of a similar nature related to the business to be conducted
by DiamiR involving methods of using small RNA from bodily fluids for diagnosis and monitoring of neurodegenerative diseases. Subsequent
to founder’s initial investment, one of its founders made a cash contribution of $100,000 for 14,265 shares of common stock.

<div align='center'>126</div>

Founders Notes

In 2014, DiamiR issued convertible notes to two of DiamiR’s founders
under which DiamiR borrowed an aggregate total of $425,000, which matured in July 2019. In July 2019, the notes were amended and the due
dates for principal and accrued interest were extended to December 31, 2022. In March 2023, DiamiR cancelled the prior notes and entered
into new notes with these same founders under which DiamiR borrowed an aggregate total of $492,016 (the “2023 Notes”); the
2023 Notes mature in December 31, 2026. The 2023 Notes have a 4% interest rate per annum, compounded monthly. The 2023 Notes are convertible,
at the option of the holder, upon DiamiR’s next equity financing involving the Company’s sale of its equity securities to
third party investors, including upon the closing of this Offering. Upon conversion, all unpaid principal and accrued unpaid interest
on the 2023 Notes will be exchanged for DiamiR’s securities at the lowest per Share price for securities sold to third parties in
the next equity financing. Between March 2023 and August 2024, DiamiR amended and restated Kira Sheinerman’s note from time to time,
to reflect additional loans during the period. As of February 28, 202